233 related articles for article (PubMed ID: 8138256)
1. Decrease in serum levels of markers of hepatic connective tissue turnover during and after treatment of chronic hepatitis B with interferon-alpha.
Teran JC; Mullen KD; Hoofnagle JH; McCullough AJ
Hepatology; 1994 Apr; 19(4):849-56. PubMed ID: 8138256
[TBL] [Abstract][Full Text] [Related]
2. Long-term decrease in serum N-terminal propeptide of type III procollagen in patients with chronic hepatitis C treated with interferon alfa.
Suou T; Hosho K; Kishimoto Y; Horie Y; Kawasaki H
Hepatology; 1995 Aug; 22(2):426-31. PubMed ID: 7635409
[TBL] [Abstract][Full Text] [Related]
3. Long-term variations of serum laminin and procollagen III peptide in chronic HCV hepatitis after alpha-interferon therapy.
Casaril M; Capra F; Gabrielli GB; Tognella P; Rizzi A; Squarzoni S; De Maria E; Colombari R; De Sandre G; Corrocher R
Ital J Gastroenterol; 1996 Jan; 28(1):15-9. PubMed ID: 8743068
[TBL] [Abstract][Full Text] [Related]
4. Resistance to alpha interferon therapy in HCV chronic liver disease: role of hepatic fibrosis.
Di Costanzo GG; Ascione A; Lanza AG; De Luca M; Bracco A; Lojodice D; Marsilia GM; Ferbo U
Ital J Gastroenterol; 1996 Apr; 28(3):140-6. PubMed ID: 8789824
[TBL] [Abstract][Full Text] [Related]
5. Interferon-alpha 2a increases serum concentration of hyaluronic acid and type III procollagen aminoterminal propeptide in patients with chronic hepatitis B virus infection.
Zöhrens G; Armbrust T; Meyer Zum Büschenfelde KH; Ramadori G
Dig Dis Sci; 1994 Sep; 39(9):2007-13. PubMed ID: 8082511
[TBL] [Abstract][Full Text] [Related]
6. Liver stellate cells and aminoterminal peptide of type III procollagen in chronic hepatitis C treated with interferon.
Gabrielli GB; Casaril M; Stanzial AM; Colombari R; Pasino M; Corrocher R
Hepatogastroenterology; 2003; 50(54):2017-21. PubMed ID: 14696456
[TBL] [Abstract][Full Text] [Related]
7. [Serum variations of 2 markers of fibrogenesis in chronic hepatitis C treated with alpha interferon].
Soresi M; Bascone F; Agate V; Carroccio A; Barresi E; Cartabellotta A; Aragona F; Montalto G
Recenti Prog Med; 1997 Feb; 88(2):73-6. PubMed ID: 9148370
[TBL] [Abstract][Full Text] [Related]
8. A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B.
Di Bisceglie AM; Fong TL; Fried MW; Swain MG; Baker B; Korenman J; Bergasa NV; Waggoner JG; Park Y; Hoofnagle JH
Am J Gastroenterol; 1993 Nov; 88(11):1887-92. PubMed ID: 8237937
[TBL] [Abstract][Full Text] [Related]
9. [Procollagen III and laminin in chronic viral hepatopathies].
Montalto G; Soresi M; Aragona F; Tripi S; Carroccio A; Anastasi G; Magliarisi C; Barresi E; Notarbartolo A
Presse Med; 1996 Jan; 25(2):59-62. PubMed ID: 8745719
[TBL] [Abstract][Full Text] [Related]
10. Serum procollagen type III peptide in chronic hepatitis B. Relationship to disease activity and response to interferon-alpha therapy.
Giustina G; Fattovich G; De Paoli M; Guido M; Favarato S; Rugge M; Alberti A; Ruol A; Plebani M
Int J Clin Lab Res; 1996; 26(1):33-6. PubMed ID: 8739853
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of serum laminin P1, procollagen-III peptides, and N-acetyl-beta-glucosaminidase for monitoring the activity of liver fibrosis.
Schneider M; Voss B; Högemann B; Eberhardt G; Gerlach U
Hepatogastroenterology; 1989 Dec; 36(6):506-10. PubMed ID: 2693303
[TBL] [Abstract][Full Text] [Related]
12. Quantitative assessment of serum IgM anti-HBc in the natural course and during interferon treatment of chronic hepatitis B virus infection.
Marinos G; Smith HM; Naoumov NV; Williams R
Hepatology; 1994 Feb; 19(2):303-11. PubMed ID: 8294088
[TBL] [Abstract][Full Text] [Related]
13. Alpha-interferon improves liver fibrosis in chronic hepatitis C: clinical significance of the serum N-terminal propeptide of procollagen type III.
Serejo F; Costa A; Oliveira AG; Ramalho F; Batista A; De Moura MC
Dig Dis Sci; 2001 Aug; 46(8):1684-9. PubMed ID: 11508668
[TBL] [Abstract][Full Text] [Related]
14. Serum markers for connective tissue turnover in patients with chronic hepatitis B and chronic hepatitis C: a comparative analysis.
Murawaki Y; Ikuta Y; Nishimura Y; Koda M; Kawasaki H
J Hepatol; 1995 Aug; 23(2):145-52. PubMed ID: 7499785
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of interferon-gamma inducible protein 10 kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients.
Wang Y; Zhao C; Zhang L; Yu W; Shen C; Wang W; Zhen Z; Zhou J
Antiviral Res; 2014 Mar; 103():51-9. PubMed ID: 24418572
[TBL] [Abstract][Full Text] [Related]
16. Serum type III procollagen peptide and laminin (Lam-P1) detect alcoholic hepatitis in chronic alcohol abusers.
Annoni G; Colombo M; Cantaluppi MC; Khlat B; Lampertico P; Rojkind M
Hepatology; 1989 May; 9(5):693-7. PubMed ID: 2707736
[TBL] [Abstract][Full Text] [Related]
17. [Differential liver histopathological features of chronic HBV infection patients with normal and mildly elevated serum ALT].
Ying RS; Yang Z; Chen YY; Yang KL; Xiao YH; Wu LJ; Fan HM
Zhonghua Gan Zang Bing Za Zhi; 2012 Aug; 20(8):585-8. PubMed ID: 23207151
[TBL] [Abstract][Full Text] [Related]
18. Interferon alfa for chronic active hepatitis B. Long term follow-up of 62 patients: outcomes and predictors of response.
Hope RL; Weltman M; Dingley J; Fiatarone J; Hope AH; Craig PI; Grierson JM; Bilous M; Williams SJ; Farrell GC
Med J Aust; 1995 Jan; 162(1):8-11. PubMed ID: 7845310
[TBL] [Abstract][Full Text] [Related]
19. High rate of mutations in the hepatitis B core gene during the immune clearance phase of chronic hepatitis B virus infection.
Bozkaya H; Ayola B; Lok AS
Hepatology; 1996 Jul; 24(1):32-7. PubMed ID: 8707278
[TBL] [Abstract][Full Text] [Related]
20. alpha-Interferon in the treatment of chronic viral hepatitis: effects on fibrogenesis serum markers.
Capra F; Casaril M; Gabrielli GB; Tognella P; Rizzi A; Dolci L; Colombari R; Mezzelani P; Corrocher R; De Sandre G
J Hepatol; 1993 Apr; 18(1):112-8. PubMed ID: 8340603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
